D. Western Therapeutics Institute (TSE:4576) Short-Term Debt: 円99.05 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4576 D. Western Therapeutics Institute Inc TSE:4576
47 GF Score
Price 円76.00
GF Value 円68.02
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is D. Western Therapeutics Institute Short-Term Debt?

D. Western Therapeutics Institute TSE:4576 +1.33% 47 Short-Term Debt is 円99.05 Mil as of Dec. 2025. GuruFocus rates TSE:4576 with a GF Score™ of 47/100 and a GF Value™ of 円68.02 (Modestly Overvalued). The stock has 3 warning signs investors should review.

D. Western Therapeutics Institute's Short-Term Debt for the quarter that ended in Dec. 2025 was 円99.05 Mil.

D. Western Therapeutics Institute's quarterly Short-Term Debt increased from Jun. 2025 (円19.05 Mil) to Sep. 2025 (円46.55 Mil) and increased from Sep. 2025 (円46.55 Mil) to Dec. 2025 (円99.05 Mil).

D. Western Therapeutics Institute's annual Short-Term Debt increased from Dec. 2023 (円9.52 Mil) to Dec. 2024 (円19.05 Mil) and increased from Dec. 2024 (円19.05 Mil) to Dec. 2025 (円99.05 Mil).

D. Western Therapeutics Institute Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

D. Western Therapeutics Institute Short-Term Debt Related Terms

D. Western Therapeutics Institute Short-Term Debt Historical Data

* Premium members only.

The historical data trend for D. Western Therapeutics Institute's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D. Western Therapeutics Institute Short-Term Debt Chart

D. Western Therapeutics Institute Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 129.52 120.00 9.52 19.05 99.05

D. Western Therapeutics Institute Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.05 19.05 46.55 99.05 126.55
TSE:4576
47GF Score
D. Western Therapeutics Institute Inc TSE:4576
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of 円99.05 Mil mean?
D. Western Therapeutics Institute (TSE:4576) has a Short-Term Debt of 円99.05 Mil as of Dec. 2025.
Is D. Western Therapeutics Institute's Short-Term Debt too high?
D. Western Therapeutics Institute's current Short-Term Debt is 円99.05 Mil. Overall, D. Western Therapeutics Institute has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's Short-Term Debt compare to VRTX and REGN?
D. Western Therapeutics Institute's Short-Term Debt of 円99.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. D. Western Therapeutics Institute's current Short-Term Debt is 円99.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (TSE:4576) is currently considered Modestly Overvalued. The stock's GF Value™ is 円68.02, compared to a current price of 円76.00 — trading 11.7% above its estimated fair value. The current Short-Term Debt is 円99.05 Mil. D. Western Therapeutics Institute's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For D. Western Therapeutics Institute (TSE:4576), the current Short-Term Debt is 円99.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is D. Western Therapeutics Institute (TSE:4576) Overvalued in 2026?

Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued. The current stock price of 円76.00 is trading 11.7% above its estimated GF Value™ of 円68.02. GuruFocus considers D. Western Therapeutics Institute to be Modestly Overvalued.

Key valuation signals for TSE:4576:

  • Short-Term Debt: 円99.05 Mil
  • GF Value™: 円68.02 vs. price of 円76.00 (11.7% above fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the TSE:4576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

D. Western Therapeutics Institute Business Description

Other Exchanges 6DW:Germany
Address 7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
47GF Score

Get the complete analysis for TSE:4576

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円76.00
Price
円68.02
GF Value